Alkermes Welcomes Joshua Reed as New Chief Financial Officer

Alkermes Appoints Joshua Reed as Chief Financial Officer

Alkermes plc, a prominent name in the biopharmaceutical sector, has announced the appointment of Joshua Reed as its new Chief Financial Officer. This pivotal move, effective September 15, 2025, comes at an exciting time for the company as it looks to enhance its financial strategies. Mr. Reed will be reporting to Richard Pops, the CEO of Alkermes, and will become a key member of the management committee.

In his statement, Reed expressed his enthusiasm about joining Alkermes, emphasizing his eagerness to collaborate with Pops and the rest of the team. He stated, "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence, and long-term growth."

With over 30 years of experience in financial leadership, Reed has developed a robust background, particularly in the biotechnology and pharmaceutical industries. Prior to his current role, he served as CFO at Omega Therapeutics, where he was instrumental in steering the company's financial direction. His previous engagements include a significant tenure at Aldeyra Therapeutics, and a decade-long involvement with Bristol Myers Squibb, where he rose to the position of Vice President and Head of Finance Operations for both the U.S. and Puerto Rico. His experience also spans roles at prestigious financial institutions like JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank.

In addition to his impressive professional track record, Reed currently sits on the board of directors of Scholar Rock Holding Corporation, another publicly-traded biotechnology company. His academic qualifications include a Bachelor of Science degree in Finance from Rutgers University and a Master of Business Administration from the University of Michigan's Ross School of Business.

Richard Pops, the CEO of Alkermes, expressed his excitement about Reed's arrival during a crucial phase for the company. "We are pleased to welcome Joshua to Alkermes at such an exciting time in our company's evolution. Joshua brings a wealth of financial expertise and strategic insight from his extensive experience in the biopharmaceutical industry. We gain his financial acumen and dedication to excellence as we continue to focus on driving strong performance across our commercial business, advancing our pipeline, and delivering long-term shareholder value. I look forward to the positive impact he will have across our organization," stated Pops.

About Alkermes plc

Founded with the mission to advance medical innovation, Alkermes plc (Nasdaq: ALKS) is a global biopharmaceutical company dedicated to developing innovative treatments in neuroscience. The company boasts a portfolio of proprietary commercial products aimed at treating various conditions such as alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Furthermore, Alkermes is actively developing a pipeline of both clinical and preclinical candidates to address neurological disorders, including narcolepsy and idiopathic hypersomnia.

Headquartered in Dublin, Ireland, Alkermes also maintains a corporate office and research and development facility in Massachusetts, alongside a manufacturing plant in Ohio. As it continues to grow, Alkermes remains committed to enhancing patient outcomes through its innovative approaches and dedication to quality in healthcare. For more comprehensive information, be sure to check the Alkermes website at www.alkermes.com.